Newspaper: Nine deaths after AstraZeneca in Germany: –

In almost all cases, 29 out of 31, it is women aged 20 to 63 who are affected by so-called sinus vein thrombosis, writes Der Spiegel.

The last two patients registered by his Ehrlich Institute are men aged 36 and 57 respectively.

– It is very serious that several cases appear. And that’s what we’ve seen in recent weeks, that as doctors have become more aware and observed the side effects, they have discovered several cases, says medical director Steinar Madsen of Dagbladet’s Norwegian Medicines Agency.

That is why the countries are divided

– More serious

Madsen says the Norwegian Medicines Agency has not been notified of new cases of the serious disease that has been shown in some people recently vaccinated with AstraZeneca: bleeding, low platelet counts and blood clots.

– There are no new messages of this type, so it seems that is what we think, that the danger has passed more or less after 14 days.

– Fortunately, these side effects are very rare, but they are very serious. Several countries have introduced restrictions on its use, so people under the age of 55 to 65 are not vaccinated, because so far it seems that most of those affected are under this age.

However, according to Madsen, cases have also been reported in people in their 60s.

– What do the figures from Germany have to say about the additional vaccine evaluation work?

– Makes the situation more serious, he says.

AstraZenecas went on hiatus in Norway on March 11, and the Friday hiatus was extended for three weeks on Friday, until April 15. The Norwegian Medicines Agency believes there is a probable connection between severe cases of the disease and the vaccine. This is currently under investigation in several countries, including Norway, as well as in the EU.

Sweden: Norway may be right

– New numbers tomorrow

Madsen says there will be a meeting at PRAC, the so-called EU side effects committee, on Wednesday to discuss the situation.

– We hope that tomorrow the PRAC figures for all European countries will be presented. So we’ll get a better overview of the number of cases in Europe and the size of the problem, says Madsen.

Germany recently suspended use of the AstraZeneca vaccine, which was renamed Vaxzevria, but resumed it after the EU Medicines Agency, EMA, said the vaccine was “effective and safe.”

There are still regional exceptions. The Euskirchen region in North Rhine-Westphalia does not administer the vaccine to women under 55 years of age after two women had a blood clot.

The reputed Charité hospital in Berlin has also stopped administering the AstraZeneca vaccine to women under 55 years of age. This is described as a “precautionary” measure. No vaccine-associated thrombotic events have been reported in the hospital.

– You can choose for the fall.

Several vaccinated women

Der Spiegel says that in the eight federal states that share information about the sex and age of those vaccinated, about 1.78 million women under the age of 70 have received the AstraZeneca vaccine. 29 cases of blood clots correspond to one for every 61,400 vaccinated. By comparison, around 864,000 men have received Vaxzevria. Thus, there is one case of a blood clot for every 432,000 vaccinated.

Women under the age of 70 make up about two-thirds of those who have received the vaccine. The fact that more women than men have received Vaxzevria is largely explained by the fact that this vaccine was first administered to people working in the care professions.

Norway and Denmark are among the countries that have yet to use the vaccine again before more research has been done on the rare but serious cases.